Tvardi Therapeutics (TVRD) Net Cash Flow (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Net Cash Flow of -$924000.0 for Q1 2026, down 32.19% sequentially from -$699000.0 in Q4 2025, and up 95.42% YoY from -$472827.6 in Q1 2025.
Tvardi Therapeutics (TVRD) Net Cash Flow (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Net Cash Flow for 14 years, with the latest figure at -$924000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 95.42% year-over-year to -$924000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 80.28% YoY) and the FY2025 annual result came in at -$10.9 million, down 118.94% from the prior year.
- Net Cash Flow slipped to -$924000.0 in Q1 2026 per TVRD's latest filing, from -$699000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $39.6 million in Q2 2024 and troughed at -$20.2 million in Q1 2025.
- A 5-year average of $5.0 million and a median of $784000.0 in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 13880.43% in 2022, down 696.34% in 2022.
- Over 5 years, Net Cash Flow stood at $20.9 million in 2022, then slumped by 153.02% to -$11.1 million in 2023, then soared by 344.83% to $27.2 million in 2024, then slumped by 102.57% to -$699000.0 in 2025, then sank by 32.19% to -$924000.0 in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$924000.0, -$699000.0, and $784000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -924,000.00 |
| Mar 31, 2026 | -924,000.00 |
| Dec 31, 2025 | -699,000.00 |
| Dec 31, 2025 | -699,000.00 |
| Sep 30, 2025 | 784,000.00 |
| Sep 30, 2025 | 784,000.00 |
| Jun 30, 2025 | 9.21 Mn |
| Jun 30, 2025 | 9.21 Mn |
| Mar 31, 2025 | -20.18 Mn |
| Mar 31, 2025 | -20.18 Mn |
| Dec 31, 2024 | 27.18 Mn |
| Dec 31, 2024 | 27.18 Mn |
| Sep 30, 2024 | -4.17 Mn |
| Sep 30, 2024 | -4.17 Mn |
| Jun 30, 2024 | 39.62 Mn |
| Jun 30, 2024 | 39.62 Mn |
| Mar 31, 2024 | -5.19 Mn |
| Mar 31, 2024 | -5.19 Mn |
| Dec 31, 2023 | -11.10 Mn |
| Dec 31, 2023 | -11.10 Mn |